A Phase n Study on UFT Therapy for Head and Neck Squamous Cell Carcinoma

Korean Journal of Head & Neck Oncology 1994;10(1):74-79.
Published online June 30, 1994.

Jong Ouck Choi;Geon Choi;Kwang Yoon Jung

두경부 편평세포암종에 대한 UFT 투여 후 항종양효과에 관한 제2상 임상 연구

최종욱;최건;정광윤

Abstract

A Phase II study of UFT which is a mixture of Tegafur and Uracil was conducted in two institutions during past two years. Ninty-four patients of head and neck squamous cell carcinoma entered this trial, of which sixty-eight were evaluated. Among those, thirty-six cases were previously untreated and thirty-two cases were recurrent. UFT was administrated orally at a daily dose of 400mg/m² for eight weeks. The results were as following: 1) Overall response was 30.88%, but for 38.36% for 36 cases of the untreated cases, 21.88% for 32 cases of recurrent cases. 2) UFT was more effective in early stage and well differentiated squamous cell carcinoma and UFT tended to reduce the tumor size maximally at fourth or fifth week 3) There was no serious side effects except mild gastrointestinal disturbances such as nausea and vomiting, which were recovered immediately after stop or reducing a daily dose. Therefore, UFT therapy is clinically effective for head and neck squamous cell carcinoma and also may be useful for combination or palliative chemotherapy because of mild side effects.

Key Words: Head and neck squamous cell carcinoma, Chemotherapy